This site is intended for healthcare professionals

FDA accepts BLA and grants priority review for loncastuximab tesirine for treatment of relapsed or refractory diffuse large B-cell lymphoma.- ADC Therapeutics

Read time: 1 mins
Last updated:22th Nov 2020
Published:22th Nov 2020
Condition: Diffuse Large B Cell Lymphoma
Type: drug
Register free for full access to